The predominant mechanism driving hyperuricemia in gout is renal uric acid underexcretion; however, the standard urate-lowering therapy (ULT) recommendation is first-line xanthine oxidase inhibitor (XOI), irrespective of the cause of hyperuricemia. This comparative effectiveness clinical trial was undertaken to compare first-line nontitrated low-dose benzbromarone (LDBen) uricosuric therapy to XOI ULT with low-dose febuxostat (LDFeb) in gout patients with renal uric acid underexcretion.

中文翻译：

---

在一项针对肾尿酸排泄不足的痛风患者的前瞻性、随机比较疗效试验中，低剂量苯溴马隆优于低剂量非布索坦

痛风高尿酸血症的主要机制是肾脏尿酸排泄不足。然而，无论高尿酸血症的原因如何，标准降尿酸治疗 (ULT) 推荐是一线黄嘌呤氧化酶抑制剂 (XOI)。这项比较有效性临床试验旨在比较一线非滴定低剂量苯溴马隆 (LDBen) 尿酸排泄疗法与 XOI ULT 联合低剂量非布索坦 (LDFeb) 对肾尿酸排泄不足的痛风患者的治疗效果。